Open AccessGastroparesis Following Immune Checkpoint Inhibitor Therapy: A Case Series
Author(s) -
Jessica Atieh,
Jordan Sack,
Richard Thomas,
Osama E. Rahma,
Michael Camilleri,
Shilpa Grover
Publication year - 2020
Publication title -
digestive diseases and sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.14
H-Index - 124
eISSN - 1573-2568
pISSN - 0163-2116
DOI - 10.1007/s10620-020-06440-x
Subject(s) - medicine , gastroparesis , ipilimumab , pembrolizumab , nivolumab , cancer , hepatology , gastric emptying , gastroenterology , adverse effect , medical record , stomach , immunotherapy
Immune checkpoint inhibitors (ICI) have improved outcomes in patients with various malignancies; however, they can cause immune-related hepatitis and enterocolitis. Patients on ICI may also develop upper gastrointestinal symptoms and undergo measurement of gastric emptying.